Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy

In a real-world cohort of people with type 2 diabetes using a GLP-1 receptor agonist, the addition of a SGLT2 inhibitor was associated with a greater cardiovascular benefit than the addition of a sulphonylurea (pooled HR for composite cardiac endpoint of 0.76; 95% CI 0.59-0.98).

Source:

Circulation